|Bid||0.0000 x 1400|
|Ask||9.9900 x 800|
|Day's range||4.1800 - 4.7800|
|52-week range||4.0200 - 29.3250|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2022 - 18 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.67|
ST. LOUIS, January 19, 2022--PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics.
BOULDER, Colo., January 18, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today the national launch of its new GeneStrat NGS™ genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced- stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an ex
A look at the shareholders of Biodesix, Inc. ( NASDAQ:BDSX ) can tell us which group is most powerful. Institutions...